Active	Status	Sponsor type	Region	Phase	Filter
69 Active 6 Inactive 75 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

63 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yamada, Hiroshi
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Chattopadhyay, Arijit
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
Matsumori, Yasuhiko
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Tatsuoka, Yoshihisa
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Takeshima, Takao
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Singh, Sumit
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Nellikunja, Shankara
ENSURE-1, NCT05134441 / 2021-000028-36: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG, Immunic AG	Multiple Sclerosis	09/24	09/32
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Nagaseki, Yoshishige
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Yamanaka, Gaku
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Grigore, Ioana
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Pozo-Rosich, Patricia
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Rovsing, Helene
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
Shimizu, Kazutaka
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Toledo, Carlos Oseguera
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
Berciaud, Sylvie
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
Moreno, Hugo Ceja
NCT05219617 / 2022-001256-42: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults	Recruiting	3	252	Europe, US, RoW	Carisbamate	SK Life Science, Inc., SK Life Science, Inc	Seizures, Lennox Gastaut Syndrome	06/25	06/26
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome	Completed	3	270	Europe, Canada, Japan, US, RoW	Placebo, Soticlestat, TAK-935	Takeda	Lennox Gastaut Syndrome (LGS)	01/24	01/24
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome	Completed	3	144	Europe, Canada, Japan, US, RoW	Soticlestat, TAK-935, Placebo	Takeda	Dravet Syndrome (DS)	04/24	04/24
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Recruiting	3	400	Europe, Canada, Japan, US, RoW	Soticlestat, TAK-935	Takeda	Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)	05/26	05/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
COUTURIER, Justine AVEZ
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Lainez, Jose Miguel
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Alonso, Xenia
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26